Top Articles
Uncertainty in Market for Digital Path Products
Assuming a consensus that pathology’s future is digital, why are path groups slow to adopt?
CEO SUMMARY: These are uncertain times for many companies offering a range of digital pathology (DP) products to the nation’s pathologists. Sales lag behind projections that caused investors to pour money into numerous DP start-ups. One reason DP companies are not meeting sales goals is...
Why Many Pathologists Are Cautious about Digital Path
Mid-sized and smaller pathology groups often watch and wait to see what works, what doesn’t
CEO SUMMARY: In many major academic centers and the nation’s largest regional pathology supergroups, use of whole slide images and digital pathology workflow are accepted and established. This is often because of benefits unsupported by a pure return on investment. The clinical gains ou...
Pioneering DP Companies Ended Up Being Acquired
Between 2000 and 2020, new owners took control of four of five digital pathology firms
CEO SUMMARY: One reason why the adoption of a full digital pathology solution has lagged behind expectations may be attributed to the fact that four of the pioneering companies did not survive as independent businesses. They were sold and not all the new owners continued investing and dev...
Fitting Pathology AI Firms into DP Market Puzzle
Pathology AI companies need wider adoption of digital pathology before sales can increase
CEO SUMMARY: Today, the best-known developers of AI-based algorithms have been in business almost 10 years. During that time, there has been continuous improvement in the digital technologies used in digital scanning and digital image analysis. Despite these improvements, many pathology g...
Assessing the Clinical Service & Revenue Issues of the LDT Rule
Clinical labs must understand cost-benefits of their LDT offerings as they prepare for FDA compliance
BARRING INTERVENTION BY FEDERAL COURTS OR THE U.S. Congress, clinical labo...
Federal Court Issues Ban on FTC’s Noncompete Rule
Judge’s decision stops the FTC from enforcing the rule against any company nationwide.
BY NOW, MOST CLINICAL LAB MANAGERS AND PATHOLOGY PRACTICE ADMINISTROATORS ARE AWARE of the Federal T...
Unpacking the Surprises in the FDA LDT Rule
THERE ARE NOW TWO LAWSUITS IN TWO DIFFERENT COURTS CHALLENGING THE Food and Drug Administration’s Authority to r...
Don’t Be at the Mercy of the Tumultuous Healthcare Revolution
Subscribe to The Dark Report for as little as $15.27 per week.
Get the most expert business intelligence for clinical laboratories and pathology groups available today. Subscribe to The Dark Report.
CURRENT ISSUE
Volume XXXI, No. 12 – September 3, 2024
This special intelligence briefing—presented in three parts—identifies the factors retarding a faster adoption of digital pathology. Also, how to protect your lab’s proprietary LDTs and assess the financial impact of compliance.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.